Fenfluramine disrupts the mitral valve interstitial cell response to serotonin

American Journal of Pathology

Volumn 175, Issue 3, 2009, Pages 988-997

  Connolly, Jeanne M ^a   Bakay, Marina A ^a   Fulmer, James T ^a   Gorman, Robert C ^b   Gorman III, Joseph H ^b   Oyama, Mark A ^c   Levy, Robert J ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FENFLURAMINE; FLUOXETINE; GLUCOSAMINE; GLYCOSAMINOGLYCAN; MITOGEN ACTIVATED PROTEIN KINASE; PROLINE; SEROTONIN; THYMIDINE; TRITIUM;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DISRUPTION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; HUMAN CELL; LEYDIG CELL; MITOGENESIS; MITRAL VALVE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 70349238724     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081101     Document Type: Article

References (43)

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588 (Pubitemid 27360757)
2. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LEC: A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998, 339:719-724 (Pubitemid 28417354)
3. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB: Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999, 100:2161-2167
4. Volmar KE, Hutchins GM: Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 2001, 125:1555-1561 (Pubitemid 33152049)
5. McDonald PC, Wilson JE, Gao M, McNeill S, Spinelli JJ, Williams OD, Harji S, Kenyon J, McManus BM: Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol 2002, 11:251-262
6. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA: Factors associated with progression of carcinoid heart disease. N Engl J Med 2003, 348:1005-1015 (Pubitemid 36302245)
7. Dewey RB, 2nd, Reimold SC, O'Suilleabhain PE: Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007, 64:377-380
8. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356:39-46 (Pubitemid 46041752)
9. Musunuru S, Carpenter JE, Sippel RS, Kunnimalaiyaan M, Chen H: A mouse model of carcinoid syndrome and heart disease. J Surg Res 2005, 126:102-105 (Pubitemid 40726253)
10. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H: Long-term serotonin administration induces heart valve disease in rats. Circulation 2005, 111:1517-1522 (Pubitemid 40470647)
11. Hauso O, Gustafsson BI, Loennechen JP, Stunes AK, Nordrum I, Waldum HL: Long-term serotonin effects in the rat are prevented by terguride. Regul Pept 2007, 143:39-46 (Pubitemid 47212520)
12. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S: Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006, 113:81-89 (Pubitemid 43958492)
13. Rothman RB, Baumann MH: Serotonin releasing agents. Neurochemical, therapeutic, and adverse effects. Pharmacol Biochem Behav 2002, 71:825-836
14. Smith DA, Schmid EF: Drug withdrawals and the lessons within. Curr Opin Drug Discov Devel 2006, 9:38-46
15. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102:2836-2841 (Pubitemid 30954319)
16. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000, 57:75-81 (Pubitemid 30033262)
17. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL: 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003, 63:1223-1229
18. Setola V, Dukat M, Glennon RA, Roth BL: Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 2005, 68:20-33 (Pubitemid 41002941)
19. Setola V, Roth BL: Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fenphen'. Expert Opin Drug Metab Toxicol 2005, 1:377-387
20. Roth BL: Drugs and valvular heart disease. N Engl J Med 2007, 356:6-9
21. Rabkin E, Hoerstrup SP, Aikawa M, Mayer JE, Jr., Schoen FJ: Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in-vitro maturation and in-vivo remodeling. J Heart Valve Dis 2002, 11:308-314 (Pubitemid 34578445)
22. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B, Levy RJ: Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002, 161:2111-2121 (Pubitemid 35434857)
23. Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, Rosenzweig-Lipson S, McGonigle P, Levy RJ, Liang B: Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 2002, 161:2209-2218 (Pubitemid 35434865)
24. Terry DE, Chopra RK, Ovenden J, Anastassiades TP: Differential use of Alcian blue and toluidine blue dyes for the quantification and isolation of anionic glycoconjugates from cell cultures: application to proteoglycans and a high-molecular-weight glycoprotein synthesized by articular chondrocytes. Anal Biochem 2000, 285:211-219 (Pubitemid 30783650)
25. Hoyer D, Hannon JP, Martin GR: Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71:533-554 (Pubitemid 34219205)
26. Baumann MH, Ayestas MA, Dersch CM, Partilla JS, Rothman RB: Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity. Ann NY Acad Sci 2000, 914:172-186
27. Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP: Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. Am J Cardiol 2000, 85:913-915, A910
28. Tamir H, Gershon MD: Serotonin-storing secretory vesicles. Ann NY Acad Sci 1990, 600:53-66
29. Iversen L: Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol Psychiatry 2000, 5:357-362
30. Zolkowska D, Baumann MH, Rothman RB: Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 2008, 324:791-797 (Pubitemid 351185838)
31. Humphreys CJ, Beidler D, Rudnick G: Substrate and inhibitor binding and translocation by the platelet plasma membrane serotonin transporter. Biochem Soc Trans 1991, 19:95-98
32. Rudnick G, Humphreys CJ: Platelet serotonin transporter. Methods Enzymol 1992, 215:213-224
33. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, Yamamoto T, Lesch KP, Murphy DL, Hall FS, Uhl GR, Sora I: Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 2004, 29:1790-1799 (Pubitemid 39336790)
34. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152 (Pubitemid 29292403)
35. MacLean MR: Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci 1999, 20:490-495
36. Mitani Y, Mutlu A, Russell JC, Brindley DN, DeAlmeida J, Rabinovitch M: Dexfenfluramine protects against pulmonary hypertension in rats. J Appl Physiol 2002, 93:1770-1778 (Pubitemid 36082991)
37. Rochefort GY, Lemaire MC, Eder V, Hanton G, Hyvelin JM, Bonnet P, Antier D: Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension. Eur J Pharmacol 2006, 550:149-154 (Pubitemid 44572268)
38. Mast ST, Gersing KR, Anstrom KJ, Krishnan KR, Califf RM, Jollis JG: Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001, 87:989-993 (Pubitemid 32299985)
39. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531 (Pubitemid 26403928)
40. Stober G, Heils A, Lesch KP: Serotonin transporter gene polymorphism and affective disorder. Lancet 1996, 347:1340-1341
41. Pedersen HD, Haggstrom J: Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. Cardiovasc Res 2000, 47:234-243 (Pubitemid 30625286)
42. Disatian S, Ehrhart EJ 3rd, Zimmerman S, Orton EC: Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis 2008, 17:402-411
43. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ: Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001, 104:2525-2532 (Pubitemid 33104788)